HansBiomed Balance Sheet Health
Financial Health criteria checks 3/6
HansBiomed has a total shareholder equity of ₩67.1B and total debt of ₩34.3B, which brings its debt-to-equity ratio to 51.1%. Its total assets and total liabilities are ₩121.7B and ₩54.6B respectively. HansBiomed's EBIT is ₩625.6M making its interest coverage ratio 0.4. It has cash and short-term investments of ₩7.3B.
Key information
51.1%
Debt to equity ratio
₩34.30b
Debt
Interest coverage ratio | 0.4x |
Cash | ₩7.26b |
Equity | ₩67.12b |
Total liabilities | ₩54.59b |
Total assets | ₩121.72b |
Recent financial health updates
Is HansBiomed (KOSDAQ:042520) A Risky Investment?
Oct 29Is HansBiomed (KOSDAQ:042520) A Risky Investment?
Feb 29Does HansBiomed (KOSDAQ:042520) Have A Healthy Balance Sheet?
Mar 06Recent updates
HansBiomed Corporation's (KOSDAQ:042520) Low P/S No Reason For Excitement
Dec 09Is HansBiomed (KOSDAQ:042520) A Risky Investment?
Oct 29Is HansBiomed (KOSDAQ:042520) A Risky Investment?
Feb 29HansBiomed Corporation (KOSDAQ:042520) Shares Fly 25% But Investors Aren't Buying For Growth
Feb 29Are Dividend Investors Making A Mistake With HansBiomed Corporation (KOSDAQ:042520)?
Apr 10Does HansBiomed (KOSDAQ:042520) Have A Healthy Balance Sheet?
Mar 06HansBiomed's(KOSDAQ:042520) Share Price Is Down 63% Over The Past Three Years.
Jan 30Are HansBiomed's (KOSDAQ:042520) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Dec 08Declining Stock and Decent Financials: Is The Market Wrong About HansBiomed Corporation (KOSDAQ:042520)?
Nov 20Financial Position Analysis
Short Term Liabilities: A042520's short term assets (₩49.7B) do not cover its short term liabilities (₩50.1B).
Long Term Liabilities: A042520's short term assets (₩49.7B) exceed its long term liabilities (₩4.5B).
Debt to Equity History and Analysis
Debt Level: A042520's net debt to equity ratio (40.3%) is considered high.
Reducing Debt: A042520's debt to equity ratio has increased from 40% to 51.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A042520 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A042520 has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 4.1% each year.
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/25 04:23 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HansBiomed Corporation is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jong Kyung Choi | DAOL Investment & Securities Co., Ltd. |
Sang-Hun Lee | iM Securities |
Seung Kyu Jung | Kiwoom Securities Co., Ltd. |